NASDAQ Global Market • Healthcare • Biotechnology • US • USD
Merrimack Pharmaceuticals, Inc. (MACK) has a consensus analyst rating of Buy, based on 11 analysts covering the stock. Of those, 6 recommend buying, 4 recommend holding, and 1 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
